[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:bcl2-gene":3},{"name":4,"total":5,"recruiting":6,"trials":7},"BCL2 Gene",23,19,[8,16,23,29,36,42,49,55,61,67,73,79,84,90,96,102,108,114,120,126,133,139,145],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06249191","Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma",[12],"Phase 1\u002FPhase 2","RECRUITING","2026-08-26T02:18:09.641312Z","2026-07-19T19:36:05.128454Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT05091424","A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia",[20],"Phase 1","2026-08-26T02:18:37.277498Z","2026-07-19T19:36:05.117268Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT06357182","Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia",[20],"2026-08-26T02:16:16.995720Z","2026-07-05T05:32:16.751844Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":34,"content_modified":35},"NCT07321652","Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL\u002FSLL",[33],"Phase 3","2026-08-26T02:19:14.560989Z","2026-06-17T02:29:30.059389Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":40,"content_modified":41},"NCT07277231","A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia",[33],"2026-08-26T02:17:10.213717Z","2026-06-04T01:30:07.896715Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":47,"content_modified":48},"NCT06917911","Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, \"7+3\") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)",[46],"Phase 2","2026-08-26T02:18:51.009190Z","2026-05-29T15:36:40.176459Z",{"nct_id":50,"title":51,"phases":52,"status":13,"updated_at":53,"content_modified":54},"NCT06953960","A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and\u002For Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)",[12],"2026-08-26T02:16:44.178623Z","2026-05-05T02:43:28.206601Z",{"nct_id":56,"title":57,"phases":58,"status":13,"updated_at":59,"content_modified":60},"NCT06687772","CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant",[46],"2026-08-26T02:15:40.343619Z","2026-05-05T02:43:27.846837Z",{"nct_id":62,"title":63,"phases":64,"status":13,"updated_at":65,"content_modified":66},"NCT06045247","Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit\u002FFrail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma",[46],"2026-08-26T02:16:57.705506Z","2026-05-05T02:43:27.172301Z",{"nct_id":68,"title":69,"phases":70,"status":13,"updated_at":71,"content_modified":72},"NCT05800366","A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma",[46],"2026-08-26T02:15:44.309045Z","2026-05-05T02:43:26.740303Z",{"nct_id":74,"title":75,"phases":76,"status":13,"updated_at":77,"content_modified":78},"NCT05600686","Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma",[46],"2026-08-26T02:16:21.385056Z","2026-05-05T02:43:29.693214Z",{"nct_id":80,"title":81,"phases":82,"status":13,"updated_at":34,"content_modified":83},"NCT05890352","Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment",[46],"2026-05-05T02:43:28.725480Z",{"nct_id":85,"title":86,"phases":87,"status":13,"updated_at":88,"content_modified":89},"NCT05755087","Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma",[20],"2026-08-26T02:17:39.857430Z","2026-05-05T02:43:27.642521Z",{"nct_id":91,"title":92,"phases":93,"status":13,"updated_at":94,"content_modified":95},"NCT07069699","Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene",[12],"2026-08-26T02:16:54.876240Z","2026-05-05T02:43:27.175695Z",{"nct_id":97,"title":98,"phases":99,"status":13,"updated_at":100,"content_modified":101},"NCT04792489","DALY II USA\u002F MB-CART2019.1 for DLBCL",[46],"2026-08-26T02:16:01.910993Z","2026-07-19T19:36:05.118465Z",{"nct_id":103,"title":104,"phases":105,"status":13,"updated_at":106,"content_modified":107},"NCT06788964","Loncastuximab Tesirine and Rituximab as Bridging Therapy Before Standard-of-care CAR-T Therapy in Patients With Large B-cell Lymphoma (CORAL)",[46],"2026-08-26T02:18:45.196599Z","2026-07-05T05:32:16.700465Z",{"nct_id":109,"title":110,"phases":111,"status":13,"updated_at":112,"content_modified":113},"NCT03223610","Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed\u002FRefractory B-cell Lymphoma",[12],"2026-08-26T02:17:15.156099Z","2026-05-05T02:43:29.367349Z",{"nct_id":115,"title":116,"phases":117,"status":13,"updated_at":118,"content_modified":119},"NCT06834373","Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy",[46],"2026-08-26T02:16:14.341106Z","2026-05-05T02:43:26.687370Z",{"nct_id":121,"title":122,"phases":123,"status":13,"updated_at":124,"content_modified":125},"NCT05263284","8-Chloroadenosine in Combination With Venetoclax for the Treatment of Patients With Relapsed\u002FRefractory Acute Myeloid Leukemia",[20],"2026-08-26T02:18:23.582895Z","2026-06-17T19:21:16.685920Z",{"nct_id":127,"title":128,"phases":129,"status":130,"updated_at":131,"content_modified":132},"NCT07604233","Phase 1\u002F2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML",[12],"NOT_YET_RECRUITING","2026-08-26T02:16:56.877406Z","2026-05-29T15:36:40.222318Z",{"nct_id":134,"title":135,"phases":136,"status":130,"updated_at":137,"content_modified":138},"NCT07588698","Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma",[46],"2026-08-26T02:16:49.565137Z","2026-05-29T15:36:40.200627Z",{"nct_id":140,"title":141,"phases":142,"status":130,"updated_at":143,"content_modified":144},"NCT07734038","Venetoclax Plus Zanubrutinib for the Treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma",[46],"2026-08-26T02:18:56.409949Z","2026-07-30T01:46:14.458830Z",{"nct_id":146,"title":147,"phases":148,"status":149,"updated_at":150,"content_modified":151},"NCT04739813","Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed\u002FRefractory B-cell Lymphoma",[20],"ACTIVE_NOT_RECRUITING","2026-08-03T03:23:28.660374Z","2026-05-05T02:43:28.883413Z"]